Artiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) issued its quarterly earnings data on Tuesday. The company reported ($0.84) earnings per share (EPS) for the quarter, FiscalAI reports.

Artiva Biotherapeutics Trading Up 6.5%

NASDAQ:ARTV opened at $6.08 on Wednesday. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $7.36. The firm has a market capitalization of $149.26 million, a price-to-earnings ratio of -2.36 and a beta of 2.16. The business’s 50-day moving average price is $4.63 and its two-hundred day moving average price is $3.90.

Analyst Ratings Changes

A number of equities research analysts have commented on ARTV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Wednesday. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Finally, HC Wainwright upped their price objective on Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $41,000. Bank of America Corp DE boosted its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $53,000. Qube Research & Technologies Ltd acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $58,000. Finally, Jane Street Group LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.